Saqib Islam, SpringWorks CEO

Spring­Works Ther­a­peu­tics ready to launch new­ly-ap­proved desmoid tu­mor treat­ment af­ter three-month de­lay

Spring­Works Ther­a­peu­tics won FDA ap­proval for its desmoid tu­mor treat­ment Og­siveo on Mon­day, fol­low­ing a three-month reg­u­la­to­ry hic­cup.

Desmoid tu­mors are rare but lo­cal­ly ag­gres­sive tu­mors that grow with ten­dril-like fil­a­ments and can range from the size of a peach to a foot­ball, CEO Saqib Is­lam told End­points News. While they don’t metas­ta­size, they have a high rate of re­cur­rence, even with surgery, or in some cas­es, am­pu­ta­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA